Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Placebo Arm

Background:
Sparse data are available about the natural history of hemoglobin (Hb) level trends in contemporary patients with anemia, chronic kidney disease (CKD), and type 2 diabetes mellitus. We intended to describe Hb level trends over time with no or minimal administration of erythropoiesis-stimulating agents.

Study Design:
Prospective clinical trial cohort.

Setting & Participants:
2,019 individuals with type 2 diabetes, moderate anemia, and CKD from the placebo arm of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) followed up for 2.3 years with an average of 32 monthly Hb level determinations per patient. Darbepoetin alfa was administered only if Hb level decreased to

Source: American Journal of Kidney Diseases - November 19, 2012 Category: Urology & Nephrology Authors: Hicham Skali, Julie Lin, Marc A. Pfeffer, Chao-Yin Chen, Mark E. Cooper, John J.V. McMurray, Allen R. Nissenson, Giuseppe Remuzzi, Jerome Rossert, Patrick S. Parfrey, Nairne W. Scott-Douglas, Ajay K. Singh, Robert Toto, Hajime Uno, Peter Ivanovich Tags: Dialysis Source Type: research